Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
From structure to clinic: Design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer's disease.
Brown AJH, Bradley SJ, Marshall FH, Brown GA, Bennett KA, Brown J, Cansfield JE, Cross DM, de Graaf C, Hudson BD, Dwomoh L, Dias JM, Errey JC, Hurrell E, Liptrot J, Mattedi G, Molloy C, Nathan PJ, Okrasa K, Osborne G, Patel JC, Pickworth M, Robertson N, Shahabi S, Bundgaard C, Phillips K, Broad LM, Goonawardena AV, Morairty SR, Browning M, Perini F, Dawson GR, Deakin JFW, Smith RT, Sexton PM, Warneck J, Vinson M, Tasker T, Tehan BG, Teobald B, Christopoulos A, Langmead CJ, Jazayeri A, Cooke RM, Rucktooa P, Congreve MS, Weir M, Tobin AB. Brown AJH, et al. Among authors: hudson bd. Cell. 2021 Nov 24;184(24):5886-5901.e22. doi: 10.1016/j.cell.2021.11.001. Cell. 2021. PMID: 34822784 Free article. Clinical Trial.
The pharmacology of TUG-891, a potent and selective agonist of the free fatty acid receptor 4 (FFA4/GPR120), demonstrates both potential opportunity and possible challenges to therapeutic agonism.
Hudson BD, Shimpukade B, Mackenzie AE, Butcher AJ, Pediani JD, Christiansen E, Heathcote H, Tobin AB, Ulven T, Milligan G. Hudson BD, et al. Mol Pharmacol. 2013 Nov;84(5):710-25. doi: 10.1124/mol.113.087783. Epub 2013 Aug 26. Mol Pharmacol. 2013. PMID: 23979972 Free PMC article.
FFA4/GPR120: Pharmacology and Therapeutic Opportunities.
Milligan G, Alvarez-Curto E, Hudson BD, Prihandoko R, Tobin AB. Milligan G, et al. Among authors: hudson bd. Trends Pharmacol Sci. 2017 Sep;38(9):809-821. doi: 10.1016/j.tips.2017.06.006. Epub 2017 Jul 19. Trends Pharmacol Sci. 2017. PMID: 28734639 Free PMC article. Review.
Chemogenetics defines receptor-mediated functions of short chain free fatty acids.
Bolognini D, Barki N, Butcher AJ, Hudson BD, Sergeev E, Molloy C, Moss CE, Bradley SJ, Le Gouill C, Bouvier M, Tobin AB, Milligan G. Bolognini D, et al. Among authors: hudson bd. Nat Chem Biol. 2019 May;15(5):489-498. doi: 10.1038/s41589-019-0270-1. Epub 2019 Apr 15. Nat Chem Biol. 2019. PMID: 30992568 Free article.
Peptides derived from the SARS-CoV-2 receptor binding motif bind to ACE2 but do not block ACE2-mediated host cell entry or pro-inflammatory cytokine induction.
Mahindra A, Tejeda G, Rossi M, Janha O, Herbert I, Morris C, Morgan DC, Beattie W, Montezano AC, Hudson B, Tobin AB, Bhella D, Touyz RM, Jamieson AG, Baillie GS, Blair CM. Mahindra A, et al. PLoS One. 2021 Nov 18;16(11):e0260283. doi: 10.1371/journal.pone.0260283. eCollection 2021. PLoS One. 2021. PMID: 34793553 Free PMC article.
Biased M1 muscarinic receptor mutant mice show accelerated progression of prion neurodegenerative disease.
Scarpa M, Molloy C, Jenkins L, Strellis B, Budgett RF, Hesse S, Dwomoh L, Marsango S, Tejeda GS, Rossi M, Ahmed Z, Milligan G, Hudson BD, Tobin AB, Bradley SJ. Scarpa M, et al. Among authors: hudson bd. Proc Natl Acad Sci U S A. 2021 Dec 14;118(50):e2107389118. doi: 10.1073/pnas.2107389118. Proc Natl Acad Sci U S A. 2021. PMID: 34893539 Free PMC article.
83 results